Clinical trials
Embryonal Rhabdomyosarcoma clinical trials
Below are recruiting embryonal rhabdomyosarcoma clinical trials, each written for real people, not researchers. We’re tracking 6 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03382158Recruiting
Learn about DICER1-related tumors through a patient registry
This registry collects information about people with known or suspected DICER1-related conditions, including certain rare chest and other tumor types. It helps doctors and researchers understand these conditions better and may support future studies.
Minneapolis, MinnesotaAges birth–100 years - NCT05304585RecruitingPhase 3
Chemo for children with early, low-risk fusion-negative rhabdomyosarcoma
This Phase 3 study tests a chemotherapy plan for children and teens with newly diagnosed, very low-risk or low-risk rhabdomyosarcoma that does not have certain gene fusions (FOXO1 fusion negative). The goal is to see if this treatment can work well while limiting side effects by matching therapy to early-stage risk.
Birmingham, AlabamaAges Up to 21 years - NCT06669013RecruitingPhase 3
Chemo-immunotherapy for young people with bone or soft tissue sarcoma
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to chemotherapy can help young people whose bone or soft tissue sarcoma has come back or hasn't responded to previous treatment.
Saint PetersburgAges Up to 18 years - NCT07148050RecruitingPhase 1
CAR T-cell therapy for children with solid tumors
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
Seattle, WashingtonAges 1–26 - NCT06198296RecruitingPhase 1
Armored CAR T cells for GPC3-positive solid tumors
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
Houston, TexasAges Up to 21 years - NCT07172958RecruitingPhase 1
Immune cell therapy for children with certain solid tumors
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
Washington D.C., District of ColumbiaAges 1–23
Hear when a new Embryonal Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for embryonal rhabdomyosarcoma?
- Yes. Clin2 currently lists 6 recruiting embryonal rhabdomyosarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a embryonal rhabdomyosarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a embryonal rhabdomyosarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.